Cyanotis Herb Extract Veterinary Grade API is a purified and standardised ecdysteroid fraction obtained from the aerially grown tissues of Cyanotis arachnoidea C. B. Clarke (Commelinaceae). The material is not a crude botanical powder or a feed additive; it is produced by ethanol-water extraction, filtration, adsorptive purification, vacuum concentration, and drying to a controlled particle size. The active constituent is 20-hydroxyecdysone, CAS 5289-74-7. The product designator CYP-VET-E90 identifies a veterinary-grade active pharmaceutical ingredient with assay of 90.0% to 105.0% 20-hydroxyecdysone on the dried basis by high-performance liquid chromatography. Total ecdysteroid content is specified at not less than 95.0%. The extract is supplied for incorporation into tablets, capsules, powders, granules, medicated premixes, oral solutions, and injectable formulations. cGMP-controlled release parameters apply to residual solvents, elemental impurities, microbial enumeration, and particle size distribution.

A Standardised Ecdysteroid-Enriched Fraction with Defined Particle and Moisture Limits

The appearance is an off-white to pale yellow powder. Loss on drying measured according to Ph. Eur. 2.2.32 is controlled at not more than 5.0%. Residue on ignition by Ph. Eur. 2.4.16 is limited to ≤ 5.0%. Particle size distribution is specified by laser diffraction, with D90 ≤ 250 µm in the standard milled grade and D90 ≤ 150 µm for direct compression grade. Bulk density falls between 0.25 g/mL and 0.45 g/mL by USP <616> Method I. The powder is hygroscopic; when stored above 60% relative humidity, caking and feed-frame bridging can occur. Pre-drying at 45 °C under vacuum for 4 h to 6 h is recommended before dry blending.

The particle size specification is not arbitrary. In low-shear tumble blending with dextrose or ground corn carriers, a particle size distribution with excessive fines below 45 µm causes assay segregation and poor content uniformity. Milling on a pin mill with classifier speed adjusted to maintain D90 ≤ 250 µm and D10 above 20 µm reduces segregation while retaining acceptable flow. These values are representative control points for veterinary solid oral dosage forms; the exact specification must be confirmed against the certificate of analysis for the delivered batch.

In tablet and capsule manufacturing, aqueous granulation introduces a process conflict. When granulation moisture exceeds 3.5% w/w, the ecdysteroid powder can plasticise at the granule surface and form hard aggregates that reduce tablet hardness uniformity. Anhydrous ethanol or isopropanol granulation is preferred, using povidone at 3% to 5% as binder. Tablet blends containing 5% to 15% API by weight have been processed on a rotary tablet press with compression force ranging from 8 kN to 18 kN; friability remains below 1.0% when measured according to USP <1216>. For capsule filling, the standard milled grade with D90 ≤ 250 µm can be filled without granulation if 0.5% to 1.0% colloidal silicon dioxide is used as a glidant and the blend moisture is maintained below 2.5% to prevent adhesion to dosing pins and tamping pins.

When Injectable Veterinary Products Require Low Endotoxin and Sterile Filtration Compatibility

The standard CYP-VET-E90 grade is not a sterile API. When the product is specified for injectable dosage forms, the manufacturer must apply aseptic processing or terminal sterilisation after formulation. Bacterial endotoxin limits are dosage-form dependent; a common release expectation for parenteral-grade dry extracts is not more than 0.5 EU/mg, but this limit must be derived from the maximum dose and route of administration in the target species. Bioburden of the API is controlled to ≤ 100 CFU/g total aerobic microbial count and ≤ 10 CFU/g total combined yeasts and moulds by USP <61>; compliance with USP <62> is required for absence of Escherichia coli and Salmonella species.

20-hydroxyecdysone has limited aqueous solubility in pure water at neutral pH. Injectable formulations often require co-solvents such as polyethylene glycol 300, propylene glycol, or ethanol, or pH adjustment from pH 4.0 to pH 6.0. High pH above 8.0 should be avoided because degradation of ecdysteroids can occur under strongly alkaline conditions. Sterile filtration through a 0.22 µm polyvinylidene fluoride membrane may be possible after complete dissolution; if the active ingredient remains suspended, terminal sterilisation by moist heat at 121 °C for 15 min is acceptable only if stability data support the thermal exposure. Published data for this specific configuration is limited; forced degradation studies under VICH GL3(R) should be conducted.

Stability assessment for veterinary premixes and oral solutions is performed according to VICH GL3(R). The dry powder is reasonably stable when protected from light and humidity, but the data that support a single universal retest period are limited. In medicated premixes containing organic acid preservatives, the ecdysteroid content can decline if the premix is exposed to high temperature and moisture for prolonged storage. Separated real-time stability chambers maintain 25 °C/60% RH and 40 °C/75% RH; assay, moisture, and microbial limits are monitored at 0, 3, 6, 12, 18, and 24 months. Results should be generated for the specific end-use formulation because the API interacts with excipients differently in oily vehicles, polyethylene glycol-based solutions, and dry mineral premixes.

What Distinguishes a Veterinary Grade API from Crude Cyanotis Powder and Feed-Grade Extracts?

Crude Cyanotis powder typically contains much lower concentrations of 20-hydroxyecdysone and carries higher microbial, heavy metal, and residual solvent burdens. A feed-grade extract may be standardised to 50% ecdysteroid content but is not released under the same cGMP controls for residual solvents and elemental impurities. The veterinary-grade CYP-VET-E90 differs in three measurable ways: assay standardisation, contaminant limits, and particle engineering. The assay value is controlled with 90.0% to 105.0% 20-hydroxyecdysone, whereas crude powder from field-grown biomass often ranges from 0.5% to 2.0% on a dry weight basis. Residual solvent limits follow VICH GL18 or ICH Q3C; the specification for ethanol, isopropanol, and other extraction solvents must be below the permitted daily exposure limits. Elemental impurities are assessed using an ICH Q3D-based risk profile, with arsenic, cadmium, lead, and mercury normally controlled below 1 ppm, 0.5 ppm, 5 ppm and 0.5 ppm respectively in a high-purity pharmaceutical extract. These figures are standard release limits, not process maxima; batch-specific data must be reviewed.

Compared with extracts from Leuzea carthamoides, Cyanotis-derived material can be enriched to a high 20-hydroxyecdysone content with a relatively simpler ecdysteroid profile. However, the presence of co-extracted polyphenols and chlorophyll derivatives can still occur if purification is incomplete. The veterinary-grade API therefore includes an identification test by thin-layer chromatography or HPLC fingerprint to distinguish it from lower-grade Cyanotis extracts and to confirm the absence of unknown ecdysteroid analogues.

Pharmacopoeial and Contaminant Limits: A Release Checklist

The following table provides a representative release specification for CYP-VET-E90. All limit values are normative release targets, not stability endpoints. The batch certificate of analysis should be compared with the pharmacopoeial or regulatory filing for the final veterinary medicinal product.

In Direct Compression, What Excipient Ratios Prevent Punch Sticking and Lamination?

Punch sticking and lamination are the principal compaction defects seen with the direct compression grade. The extract contains polar hydroxyl groups that can interact with moisture and metal surfaces. In direct compression trials on a single-punch press and on a 16-station rotary press, formulations with 50% to 65% microcrystalline cellulose, 20% to 30% lactose monohydrate, 5% to 10% crospovidone disintegrant, and 0.5% magnesium stearate produced tablets with acceptable hardness and disintegration. Sodium stearyl fumarate at 1.0% can be used when magnesium stearate is undesirable. Punch-penetration depth should be maintained between 2 mm and 4 mm; deeper penetration increases dwell time but may cause capping if the blend is over-lubricated. The API should not be wet-granulated with amines or strong alkalising agents because ecdysteroid degradation accelerates in alkaline conditions.

Blending time is a critical threshold. When magnesium stearate is added, blending beyond 15 min in a V-blender at 25 rpm can reduce tablet tensile strength by more than 20%, measured according to USP <1217>. This is due to shear-induced coating of the API and filler particles with hydrophobic lubricant. The use of 0.5% magnesium stearate with total blend time of 5 min to 10 min limits this effect.

In medicated premix production, the API should be preblended with a small portion of inert carrier before introduction into a main mixer. A two-stage mixing process in a ribbon blender or paddle mixer at 25 rpm for 10 min typically reduces active content variability below 3% relative standard deviation, measured by sampling at 10 points. Carrier selection matters: ground corn with particle size between 600 µm and 1000 µm produces better drug distribution than fine limestone or salt. Oral solutions can be prepared from the dry API by dissolution in a mixture of propylene glycol and purified water, with gentle heating to 40 °C; heating above 60 °C is not recommended unless stability data support the exposure. The pH of the finished solution should be kept between 4.0 and 6.5 to balance solubility and chemical stability.

Dosage-Form Integration Matrix for the Veterinary API

Each dosage form imposes a separate set of process controls. The matrix below lists the relevant unit operation, the critical process variable, and the standard or equipment class used for verification. The limits shown are representative process control points for qualification batches and are not stability specifications.

How Do pH and Thermal Stress Interact During Wet Granulation and Liquid Compounding?

Thermal degradation of 20-hydroxyecdysone in dry extract is limited at temperatures below 60 °C. However, when the API is hydrated in acidic or alkaline conditions, degradation can accelerate. Acid-catalysed hydrolysis of the ecdysteroid hydroxyl groups may occur below pH 3.0. Alkaline conditions above pH 8.0 have been associated with colour darkening and loss of assay. The granulation and solution-processing window should therefore be maintained between pH 4.0 and pH 6.5. If a formulation requires pH outside this range, forced degradation studies according to VICH GL3(R) are necessary to justify the process. The use of strong oxidising agents should be avoided entirely, as oxidation of the ecdysteroid ring system can produce unknown degradation peaks that complicate chromatographic assay.

Spray drying of the extract is performed at inlet temperature typically 160 °C to 180 °C and outlet temperature below 80 °C. The contact time is short; nevertheless, the product specification for moisture and assay is confirmed after drying. If the API is re-dried in a tray dryer, the bed depth should not exceed 2 cm to prevent uneven heat transfer and localised overheating at the tray surface. Residual solvent content is minimised by the drying step; the release certificate should confirm that ethanol and isopropanol are below the limits set by ICH Q3C.

During line clearances, the API can adhere to stainless steel surfaces if discharged while hot and humid. Cleaning validation should monitor 20-hydroxyecdysone residues by HPLC-MS/MS in rinse samples; the acceptance limit should be derived from the permitted daily exposure for the target species.